Emery Pharma Expands Analytical Services to Support Biopharma Companies Affected by the BIOSECURE Act
September 12, 2024– In response to the recent passage of the BIOSECURE Act, which seeks to reduce U.S. dependence on foreign biotechnology firms, particularly in China, Emery Pharma is pleased to announce expanded capabilities to support companies transitioning their research and development efforts to United States based service providers. With our FDA-registered and DEA-licensed facility in Alameda, California, Emery Pharma is well-positioned to assist companies as they adapt to the new regulatory requirements and shift away from foreign contract research organizations (CROs).
The BIOSECURE Act, passed by the U.S. House of Representatives on September 10, 2024, marks a significant change in the pharmaceutical and biotechnology landscape by restricting federal contracts with foreign biotech firms and encouraging U.S.-based research and development. Emery Pharma offers cutting-edge services to provide companies with reliable, compliant, and efficient domestic services.
Emery Pharma’s Expanded Capabilities Include:
- Advanced expertise in mass spectrometry, LC-MS, high-resolution mass spectrometry
- Development and analysis using ELISA assays, flow cytometry, and qPCR
- Comprehensive Chemistry, Manufacturing and Controls (CMC) support offering expertise in API and Drug Product analysis.
- Detection and analysis of small molecules, biopharmaceuticals, antibody-drug conjugates, and more
- Offering both GLP and non-GLP bioanalytical services to support drug discovery and development
- Rapid turnaround times with regulatory expertise, helping companies stay on track with R&D goals without the delays typically associated with foreign partnerships
“As companies adjust to the challenges presented by the BIOSECURE Act, recently passed by the U.S. House of Representatives, Emery Pharma stands ready to provide immediate support,” said Dr. Ron Najafi, CEO of Emery Pharma. “Our expertise in bioanalysis and mass spectrometry ensures that U.S.-based companies can continue their vital work without disruption, while remaining fully compliant and we are continuing to stay committed to helping our clients transition smoothly and continue advancing life-saving therapies.”
With a longstanding reputation as a trusted partner in the pharmaceutical and biotech sectors, Emery Pharma offers a wide array of services including support of drug development programs, bioanalytical chemistry, microbiological testing, consulting, and more. As companies shift their operations to comply with the new mandates of the BIOSECURE Act, Emery Pharma’s comprehensive services provide an ideal domestic solution.
About Emery Pharma
Emery Pharma is a U.S.-based contract research organization (CRO) offering a wide range of services including bioanalysis, mass spectrometry, microbiology, and consulting support. Located in Alameda, California, the company operates from an FDA-registered and DEA-licensed facility, providing both GLP and non-GLP services to pharmaceutical, biotech, and medical device industries. With a focus on fast project turnaround and compliance, Emery Pharma ensures clients can meet their critical research deadlines.
For more information, visit EmeryPharma.com or contact us at info@emerypharma.com.
